Furthermore, inhibiting ERK1/2 may overcome the limitations of upstream RAF or MEK inhibitors, and LY3214996 (an ERK1/2 inhibitor) has shown promising anti-tumor activity in preclinical studies and acceptable safety in trials, further supporting its efficacy as monotherapy or in combination therapy (48, 49). This evidence concerns the gene MAPK3 and neoplasm.